Follow the shifts shaping medtech and biopharma innovation.
first-in-human · clinical trial · clinical research · regulatory · FDA · medical device
Follow the shifts shaping medtech and biopharma innovation. Regulatory changes, digital submission systems, and new industry partnerships are influencing how clinical development moves forward across Latin America and beyond.
• Mexico introduces a reliance framework for device approvals.
• Argentina advances digital regulatory submissions.
• Biosimilar partnerships expand across Latin America.
• Medtech industry calls for greater FDA transparency.
• Long-term partnerships reshape biopharma development.
• Leadership and collaboration drive clinical research forward.
Take a closer look at the trends shaping the future of clinical development. 👇
Mexico is introducing a reliance-based regulatory pathway that allows medical device approvals to draw on prior evaluations conducted by trusted international authorities. By recognizing decisions from regulators such as the U.S. FDA and European agencies, the framework aims to streamline review processes while maintaining strong standards for safety and performance.
The approach reflects a broader effort to modernize regulatory systems and reduce administrative duplication, potentially allowing innovative technologies to reach the Mexican healthcare market more efficiently.
Why It Matters: Regulatory reforms that simplify approval pathways can shorten development timelines and strengthen Mexico's position as a strategic gateway for launching and expanding medical technologies across Latin America.
Argentina is strengthening its regulatory infrastructure by requiring certified digital signatures for submissions to the national health authority. The move supports a more secure and efficient framework for regulatory filings, enabling sponsors and regulatory representatives to submit documentation electronically while ensuring authenticity and traceability.
Digital authentication is becoming an essential component of regulatory compliance as health authorities across Latin America continue transitioning toward fully digital submission systems.
Does your company need accelerated first-in-human clinical trial results?
Overcome the complex landscape of first-in-human clinical trials with confidence. Whether you're advancing Medtech devices, Biopharma therapies, or Radiopharmaceutical innovations, bioaccess® delivers expert solutions to help you succeed.
Bring your innovations to market faster with Latin America's first-in-human trial experts.
Schedule your first-in-human trial consultation at bioaccessla.com
Industry stakeholders are urging the U.S. Food and Drug Administration to provide more clarity around staffing and operational resources as negotiations continue for the next Medical Device User Fee Amendments (MDUFA) agreement. Concerns have been raised that limited staffing could affect the consistency and speed of medical device review timelines.
Greater transparency around agency resources and performance metrics is being viewed as important for maintaining confidence in the regulatory process and supporting a predictable pathway for device approvals.
Key Points:
• Industry groups are requesting clearer insight into FDA staffing levels and review capacity
• Workforce constraints could influence device approval timelines
• Transparency is being emphasized as negotiations for the next MDUFA agreement continue
A new collaboration between SteinCares and Shilpa Biologicals is set to expand the commercialization of biosimilar therapies across Latin America. The partnership focuses on bringing a portfolio of biologic treatments to markets throughout the region, supporting broader patient access to advanced therapies.
As healthcare systems continue to seek cost-effective alternatives to high-priced biologics, biosimilars are playing an increasingly important role in expanding treatment availability while maintaining comparable safety and efficacy standards.
Bottom Line: Strategic collaborations are accelerating the introduction of biosimilars in Latin America, highlighting the region's growing importance in the global biopharmaceutical landscape.
The biopharmaceutical development landscape is becoming increasingly complex as companies navigate advanced therapies, evolving regulatory requirements, and global supply chains. As a result, organizations are placing greater emphasis on building long-term partnerships that can provide specialized expertise and operational support throughout the product lifecycle.
Sustained collaboration allows companies to manage development challenges more effectively by leveraging the capabilities of experienced partners across research, clinical development, manufacturing, and regulatory strategy. These relationships can help streamline processes, reduce operational risks, and support more coordinated development programs.
Tina Soulis, founder of Alithia Life Sciences, highlights how strong leadership and strategic thinking are becoming essential for navigating the evolving clinical research landscape. As drug and device development grow more complex, life sciences organizations are placing greater emphasis on building teams that can combine scientific expertise with operational execution.
The discussion also underscores the importance of collaboration across sponsors, research organizations, and specialized partners. Coordinated partnerships are increasingly seen as critical to advancing innovative therapies while managing the operational and regulatory demands of modern clinical development.
Bottom Line: Leadership that integrates scientific insight with strategic collaboration is playing a growing role in shaping the future of clinical research.
← All Global Trial Accelerators editions · Contact bioaccess®